PEPTIDE COMPARISON

CJC-1295 vs Tesamorelin

An unapproved endocrine research peptide compared with an indication-specific approved medicine.

QUICK ANSWER

CJC-1295 vs Tesamorelin: the main difference.

Tesamorelin has much stronger decision-grade evidence for its labeled population. That does not make it a general weight-loss drug, while CJC-1295's hormone effects do not establish clinical benefit.

Decision field	CJC-1295	Tesamorelin
Human research	Small pharmacology studies	Multiple indication-specific randomized trials
Mechanism	Long-acting GHRH analog	GHRH analog
FDA status	Not approved	Approved for one narrow indication
Primary endpoint context	Hormone and IGF-1 changes	HIV-associated excess abdominal fat
Evidence confidence	Low for clinical outcomes	High only for the labeled population

SOURCES

CJC-1295 vs Tesamorelin sources.

Human trial / 2006Prolonged stimulation of growth hormone and IGF-1 by CJC-1295PubMed WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2025EGRIFTA WR prescribing informationU.S. FDA Human trial / 2010Pooled analysis of two Phase 3 tesamorelin trialsPubMed

CJC-1295 vs Tesamorelin: the main difference.

CJC-1295 vs Tesamorelin sources.

Questions related to CJC-1295 vs Tesamorelin.

Compare the next decision.